The US/China Trade Agreement: what could it mean for the Pharma Industry?

Following a long period of negotiation, Phase I of the US-China Trade Agreement was published on 15 January 2020. An important element of the negotiations from the US side had focussed on the need for China to recognise and strengthen the protection of intellectual property (IP) rights held by US companies in China. Chapter 1 of the Agreement is of particular relevance to pharmaceutical companies as it contains a broad range of measures that, if implemented into law and properly enforced, could have a significant beneficial effect for IP rights owners in China.

Latest insights

More Insights
featured image

EPO Upholds, UPC Revokes: A Tale of Diverging Views on PCSK9 Antibody Patent

2 minutes Jul 02 2025

Read More
featured image

The possible end of the Green Claims Directive: Is it all Greenwashing now?

4 minutes Jun 26 2025

Read More
Ferris wheel

Horizon Scanning 2025/2026

Jun 25 2025

Read More